Sunday, September 27

EANO Meeting - Sunday, September 27, 2026

Note that the programme is subject to change and will be continuously updated.
All times are in Central European Summer Time (CEST).

08:00-09:00

Michael Platten, Germany
President EANO


09:00-10:30

Chairs: TBC, TBC

JS07.1 Imaging biomarkers of neurocognition: how to integrate imaging in treatment planning
Laurien de Roeck, Belgium

JS07.2 Mechanisms of Radiotherapy-induced neurotoxicity
Rifaquat Rahman, United States

JS07.3 How to assess the tumor growth and response to treatments (including imaging biomarkers neurocognitive damage)
TBC, -

JS07.4 Radiotherapy and systemic agent combination in preclinical models and clinical settings
TBC, -

 

 

Chairs: Maximilian Mair, TBC

JS08.1 Molecular basics of PET imaging in neuro-oncology
Nelleke Tolboom, Netherlands

JS08.2 PET imaging in clinical practice: experience and guidelines
Norbert Galldiks, Germany

JS08.3 The emerging role of PET imaging for clinical trials
Nathalie Albert, Germany

JS08.4 Current status and future directions of theranostics in neuro-oncology
Matthias Preusser, Austria

 

 

Chairs: TBC, TBC

OS12.1 Individualized interventions for neuropsychological problems in pediatric brain tumors
Marita Partanen, Netherlands

OS12.2 Interventions for improving neurocognitive functioning in paediatric brain tumour survivors
TBC, -

OS12.3 Latest symptom management insights in adults with brain tumours: spotlight on epilepsy management
Edward Avila, United States

OS12.4 The role of rehabilitation in optimising quality of survival
Anna Zanotto, United States


10:30-11:00 Coffee break


11:00-12:30

Chairs: TBC, TBC

JS09.1 Cancer Neuroscience
Richard Drexler, United States

JS09.2 Oncolytic virotherapy for glioblastoma
Eva Galanis, United States

JS09.3 DNA damage response inhibitors for the treatment of glioblastoma
Anthony Chalmers, United Kingdom

JS09.4 (Personalized) vaccination for glioblastoma
Katharina Sahm, Germany

Chairs: TBC, TBC

OS13.1 Injectable bioresorbable conductive hydrogels as active post-resection therapeutic platforms
TBC, -

OS13.2 Technical considerations and next-generation application of interstitial fluid and longitudinal CSF monitoring
Terry Burns, United States

OS13.3 Brain injury biomarkers to quantify neurobiological cost of tumor treatment
Thomas Skoglund, Sweden

OS13.4 Human CNS Tissue Effects in 5-ALA Sonodynamic Therapy
Shwetal Mehta, United States

Chairs: TBC, TBC

JS10.1 Advanced MRI Techniques in glioma follow-up: when and how?
Albert Pons-Escoda, Spain

JS10.2 Chemical Exchange Saturation Transfer
TBC, -

JS10.3 Magnetic Resonance Spectroscopy for molecular diagnosis and follow-up in glioma
TBC, -

JS10.4 Pioneering pre-clinical MR imaging of glioma
TBC, -


12:30-12:45

Michael Platten, Germany
EANO President

Giuseppe Minniti, Italy
President EANO Meeting 2026